Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Treatment options for patients with heavily pretreated relapsed and/or refractory multiple myeloma remain limited. We evaluated a novel therapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label, multicenter, phase 1, dose-escalation study. Patients who rel...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood
मुख्य लेखकों: Shah, Jatin J., Stadtmauer, Edward A., Abonour, Rafat, Cohen, Adam D., Bensinger, William I., Gasparetto, Cristina, Kaufman, Jonathan L., Lentzsch, Suzanne, Vogl, Dan T., Gomes, Christina L., Pascucci, Natalia, Smith, David D., Orlowski, Robert Z., Durie, Brian G. M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2015
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643003/
https://ncbi.nlm.nih.gov/pubmed/26384354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-643320
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन